Maintenance Capecitabine After mFOLFIRINOX Improves PFS in Metastatic Pancreatic Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Shehata MA, Alhanafy AM, Hassan ME, et al.
Sep 29, 2026 · Published in: Asian Pacific Journal of Cancer Prevention : APJCP
Capecitabine maintenance boosts survival in metastatic pancreatic cancer.
Busulfan Precision Dosing Evolves From TDM Toward Model-Informed Dosing
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Zhang XY, Li Y, Xu J, et al.
Sep 26, 2026 · Published in: Pharmaceutics
Also in Oncology, Pediatrics
Optimizing busulfan dosing in pediatric transplants involves bridging TDM with precision models.
FORTA-Based Pharmacist Review Cuts Medication Problems in Older Cancer Patients
Analysis Ambulatory Care / MTM Confirmatory Grade: Moderate
Degen M, Kopp-Schneider A, Vlaski T, et al.
Sep 23, 2026 · Published in: Journal of Internal Medicine
Also in Oncology, Clinical Practice, Geriatrics
Pharmacist-led reviews reduce inappropriate medication in older cancer patients.
ADCs Reshape Frontline Metastatic Triple-Negative Breast Cancer
Analysis Oncology Pharmacy Confirmatory Grade: Moderate
Browne IM, Esteban Garcia M, Okines AFC
Sep 22, 2026 · Published in: Oncology Research
New therapies offer hope for aggressive TNBC.
Standardized Oral Care Cuts Severe Mucositis in Leukemia Induction
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Yu F, Mao T
Sep 19, 2026 · Published in: Medicine
Standardized oral care cuts severe mucositis in leukemia chemotherapy by nearly half.
Real-World RCC Data: ICI+TKI Improves PFS, Not Survival
Analysis Oncology Pharmacy Confirmatory Grade: Low
Ohba K, Oki M, Matsuda T, et al.
Sep 16, 2026 · Published in: Cancer Medicine
TKI combos may improve initial disease control in metastatic RCC.
Panitumumab in RAS Wild-Type Left-Sided mCRC: Evidence Synthesis
Analysis Oncology Pharmacy Confirmatory Grade: Low
Kwiatkowska L, Szczuko M
Sep 15, 2026 · Published in: International Journal of Molecular Sciences
Panitumumab extends survival in metastatic colorectal cancer with precision therapy advances.
Morning neoadjuvant immunotherapy signals better survival in operable NSCLC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Yu XY, Zhai WY, Xia ZZ, et al.
Sep 12, 2026 · Published in: Frontiers in Immunology
Infusion timing may enhance survival in NSCLC treatment.
FAERS Signal Links EGFR-TKI Plus Checkpoint Inhibitor to Pneumonitis
★ Editor's Pick Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Tao J, Fu Z
Sep 12, 2026 · Published in: Frontiers in Immunology
Increased interstitial pneumonitis risk with combined NSCLC therapy.
Neoadjuvant chemoimmunotherapy plus afatinib yields high pathologic response in head and neck cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wei Z, Chen H, Wang D, et al.
Sep 12, 2026 · Published in: Journal for Immunotherapy of Cancer
New chemoimmunotherapy regimen shows promise for head and neck cancer.
Pharmacist-Led Deprescribing Halves Inappropriate Medications in Older Cancer Patients
Analysis Geriatrics / Geriatric Pharmacy Hypothesis-generating Grade: Low
Maleki S, Foo J, Zamani M, et al.
Sep 12, 2026 · Published in: Journal of Geriatric Oncology
Also in Oncology
Deprescribing cuts inappropriate medication use in cancer care for older adults.
Cisplatin adds to, does not synergize with, radiation lymphocyte apoptosis
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Sak A, Mladenov E, Alberti Y, et al.
Sep 6, 2026 · Published in: Radiation Oncology (London, England)
Cisplatin adds to radiation's apoptotic impact on cancer patients' lymphocytes.
Chitosan Nanoparticles for Thyroid Cancer: Preclinical Promise, No Clinical Data
Analysis Oncology Pharmacy Hypothesis-generating Grade: Very Low
Alyami HS, Ahmadi NA
Sep 5, 2026 · Published in: Medicine
Chitosan-based nanoparticles could revolutionize thyroid cancer treatment with targeted delivery.
ADCs Reshape Post-Chemoimmunotherapy Options in Esophageal Cancer
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Wu D, Chen W, Zhao Q, et al.
Sep 5, 2026 · Published in: Current Treatment Options in Oncology
ADCs offer hope for esophageal cancer after first-line chemoimmunotherapy fails.
Adjuvant Therapy After Neoadjuvant Immunochemotherapy Improves Survival in Resected ESCC
Analysis Oncology Pharmacy Hypothesis-generating Grade: Low
Zhang X, Gao H, Cao J, et al.
Sep 3, 2026 · Published in: Frontiers in Immunology
Postoperative adjuvant therapy enhances survival for ESCC after neoadjuvant treatment.